Should I buy or sell Eliem Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eliem Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ELYM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELYM, but not buy additional shares or sell existing shares. View ELYM analyst ratings or view top-rated stocks .

What is Eliem Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for Eliem Therapeutics' stock. Their ELYM share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price. View analysts price targets for ELYM or view top-rated stocks among Wall Street analysts .

How have ELYM shares performed in 2023?

Eliem Therapeutics' stock was trading at $3.67 at the beginning of 2023. Since then, ELYM stock has decreased by 28.9% and is now trading at $2.61. View the best growth stocks for 2023 here .

Are investors shorting Eliem Therapeutics?

Eliem Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 35,300 shares, a decrease of 14.9% from the October 31st total of 41,500 shares. Based on an average daily volume of 15,100 shares, the short-interest ratio is currently 2.3 days. Approximately 0.2% of the shares of the stock are short sold. View Eliem Therapeutics' Short Interest .

When is Eliem Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our ELYM earnings forecast .

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) announced its earnings results on Monday, November, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.19.

When did Eliem Therapeutics IPO?

(ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Who are Eliem Therapeutics' major shareholders?

Eliem Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BML Capital Management LLC (7.15%) and Silverarc Capital Management LLC (0.45%).

How do I buy shares of Eliem Therapeutics?

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Eliem Therapeutics Stock Price, News & Analysis (NASDAQ:ELYM)

$2.57

-0.03 (-1.15%)

(As of 11/29/2023 ET)

Compare

Today's Range: $2.52
▼
$2.61
50-Day Range: $2.45
▼
$2.68
52-Week Range: $2.21
▼
$4.75

Volume: 800 shs
Average Volume: 19,544 shs
Market Capitalization: $70.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Eliem Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 129.9% Upside
$6.00 Price Target
Short Interest: Healthy
0.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

684th out of 949 stocks

Pharmaceutical Preparations Industry

332nd out of 436 stocks

3.0

Analyst's Opinion

Consensus Rating
Eliem Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Eliem Therapeutics has a forecasted upside of 129.9% from its current price of $2.61.
Amount of Analyst Coverage
Eliem Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.19% of the float of Eliem Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Eliem Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eliem Therapeutics has recently decreased by 14.94%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Eliem Therapeutics does not currently pay a dividend.
Dividend Growth
Eliem Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELYM.

3.0

News and Social Media Coverage

News Sentiment
Eliem Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Eliem Therapeutics this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eliem Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.20% of the stock of Eliem Therapeutics is held by insiders.
Percentage Held by Institutions
61.78% of the stock of Eliem Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Eliem Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eliem Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eliem Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Eliem Therapeutics Stock (NASDAQ:ELYM)

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

ELYM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ELYM Stock News Headlines

November 19, 2023 | morningstar.com

Checkpoint Therapeutics Inc CKPT

November 15, 2023 | morningstar.com

Eliem Therapeutics Inc ELYM

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

September 28, 2023 | finance.yahoo.com

Eliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth Plans

July 21, 2023 | finance.yahoo.com

Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%

July 21, 2023 | msn.com

Eliem Therapeutics’ stock soars 21% premarket after company says it may sell itself

July 20, 2023 | benzinga.com

What's Happening With Eliem Therapeutics Shares Today?

July 20, 2023 | finanznachrichten.de

Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

July 20, 2023 | marketwatch.com

Eliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYM

July 20, 2023 | markets.businessinsider.com

Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?

July 20, 2023 | finance.yahoo.com

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

June 7, 2023 | markets.businessinsider.com

Stifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)

May 25, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)

May 12, 2023 | finanznachrichten.de

Eliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

May 11, 2023 | seekingalpha.com

Eliem Therapeutics GAAP EPS of -$0.84

May 11, 2023 | finance.yahoo.com

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

April 21, 2023 | finance.yahoo.com

We're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash Wisely

March 9, 2023 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)

March 7, 2023 | finanznachrichten.de

Eliem Therapeutics, Inc.: Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

March 6, 2023 | finance.yahoo.com

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

February 23, 2023 | seekingalpha.com

ELYM Eliem Therapeutics, Inc.

February 23, 2023 | finance.yahoo.com

Eliem Therapeutics slashing staff amid leadership shakeup

February 18, 2023 | finance.yahoo.com

Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce

February 10, 2023 | msn.com

Eliem Therapeutics down after announcing reprioritization plans, layoffs

February 9, 2023 | finance.yahoo.com

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

November 30, 2022 | finance.yahoo.com

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

See More Headlines

Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ELYM
CUSIP: N/A
CIK: 1768446
Web: www.eliemtx.com
Phone: 877-354-3689
Fax: N/A
Employees: 30
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $6.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +138.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,240,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -33.55%
Return on Assets: -32.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 38.76
Quick Ratio: 38.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.98 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 27,570,000
Free Float: 26,691,000
Market Cap: $69.48 million
Optionable: Not Optionable
Beta: 0.40

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Andrew Levin M.D. (Age 46)
Ph.D., Principal Financial Officer & Executive Chairman
Comp: $73k
Dr. Valerie Morisset Ph.D. (Age 53)
Chief Scientific Officer and Executive VP of Research & Development
Comp: $617.87k
Ms. Emily Pimblett (Age 39)
Principal Accounting Officer
Ms. Jo Palmer-Phillips Ph.D.
Chief Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ELYM Stock Analysis - Frequently Asked Questions

Should I buy or sell Eliem Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eliem Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ELYM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELYM, but not buy additional shares or sell existing shares.
View ELYM analyst ratings or view top-rated stocks.
What is Eliem Therapeutics' stock price target for 2024?: 1 Wall Street analysts have issued 12-month price objectives for Eliem Therapeutics' stock. Their ELYM share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price.
View analysts price targets for ELYM or view top-rated stocks among Wall Street analysts.
How have ELYM shares performed in 2023?: Eliem Therapeutics' stock was trading at $3.67 at the beginning of 2023. Since then, ELYM stock has decreased by 28.9% and is now trading at $2.61.
View the best growth stocks for 2023 here.
Are investors shorting Eliem Therapeutics?: Eliem Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 35,300 shares, a decrease of 14.9% from the October 31st total of 41,500 shares. Based on an average daily volume of 15,100 shares, the short-interest ratio is currently 2.3 days. Approximately 0.2% of the shares of the stock are short sold.
View Eliem Therapeutics' Short Interest.
When is Eliem Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our ELYM earnings forecast.

How were Eliem Therapeutics' earnings last quarter?: Eliem Therapeutics, Inc. (NASDAQ:ELYM) announced its earnings results on Monday, November, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.19.
When did Eliem Therapeutics IPO?: (ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.
Who are Eliem Therapeutics' major shareholders?: Eliem Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BML Capital Management LLC (7.15%) and Silverarc Capital Management LLC (0.45%).
How do I buy shares of Eliem Therapeutics?: Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ELYM) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial